Invivo Therapeutics Holdings Corp. NVIV
We take great care to ensure that the data presented and summarized in this overview for INVIVO THERAPEUTICS HOLDINGS CORP. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NVIV
Top Purchases
Top Sells
About NVIV
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at NVIV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 06
2023
|
Brice Foose > 10% Shareholder |
SELL
Open market or private purchase
|
Direct |
164,000
-39.31%
|
$0
$0.43 P/Share
|
|
Feb 05
2023
|
Brice Foose > 10% Shareholder |
SELL
Open market or private purchase
|
Direct |
166,000
-10.82%
|
$0
$0.29 P/Share
|
|
Dec 21
2021
|
Richard M. Toselli CEO and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
16
-0.26%
|
$0
$0.54 P/Share
|
|
Jun 21
2021
|
Richard M. Toselli CEO and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
21
-0.34%
|
$0
$0.74 P/Share
|
|
Dec 21
2020
|
Richard M. Toselli CEO and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
16
-0.26%
|
$0
$0.6 P/Share
|